Interstitial Cystitis Market Research Report and Forecast up to 2025 Interstitial Cystitis Market - Global Industry Ana | Page 2

treat severe IC conditions by blocking the pain and reducing the inflammation is
also recommended. The third phase is neurostimulation - transcutaneous electrical
nerve stimulation or sacral nerve stimulation. The fourth phase includes
administering cyclosporine to alter the immune response on the bladder, and the
fifth phase involves bladder detention or surgery. The market currently has only two
approved treatment options for IC: Elmiron (pentosan polysulfate sodium) and
Rimso-50 (dimethyl sulfoxide). Elmiron was approved on September 26, 1996, and
its patent expired on January 19, 2010. Similarly, Rimso-50 was approved prior to
January 1, 1982, and its patent expired before 2002. The current line of treatment is
dominated by off-label drug options such as antidepressants (amitriptyline),
antihistamines (hydroxyzine), and analgesics (opioid and non-steroidal) due to the
limited availability of approved therapies.
The IC therapeutics market is currently weak due to limitations regarding the
efficacy and compliance of available products. Other factors contributing to the
significant unmet needs include limited approved treatment options, lack of
awareness, and need for disease modifying therapies. Current pipeline for the IC
therapeutics market is very weak with a majority of the molecules in the early stage
of development. These significant unmet needs and weak pipeline with a majority of
the molecules in early stage pose new opportunities for new entrants.
In terms of geography, the interstitial cystitis market can be segmented into North
America, Europe, Asia Pacific, and Rest of the World (RoW). The interstitial cystitis
market is estimated to expand at a sluggish rate primarily due to the limited
availability of approved products, low diagnosis rate, and lack of new product
approvals.
Key players operating in the interstitial cystitis market are Aquinox Pharmaceuticals
Inc., Astellas Pharma Inc, Merck & Co Inc, Allergan Plc., Kytogenics Pharmaceuticals
Inc., BELLUS Health Inc, UCB SA, Lipella Pharmaceuticals Inc, Urigen
Pharmaceuticals Inc, and Xigen SA.
The report offers a comprehensive evaluation of the market. It does so via in-depth
qualitative insights, historical data, and verifiable projections about market size. The
projections featured in the report have been derived using proven research
methodologies and assumptions. By doing so, the research report serves as a
repository of analysis and information for every facet of the market, including but
not limited to: Regional markets, technology, types, and applications.
Get accurate market forecast and analysis on the Interstitial Cystitis
Market Request a sample to stay abreast on the key trends impacting this
market.
http://www.transparencymarketresearch.com/sample/sample.php?
flag=B&rep_id=25523
The study is a source of reliable data on: